MX2017015404A - Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas. - Google Patents

Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.

Info

Publication number
MX2017015404A
MX2017015404A MX2017015404A MX2017015404A MX2017015404A MX 2017015404 A MX2017015404 A MX 2017015404A MX 2017015404 A MX2017015404 A MX 2017015404A MX 2017015404 A MX2017015404 A MX 2017015404A MX 2017015404 A MX2017015404 A MX 2017015404A
Authority
MX
Mexico
Prior art keywords
gram
lipoproteins
antigens
outer membrane
membrane vesicles
Prior art date
Application number
MX2017015404A
Other languages
English (en)
Inventor
Louis Marten Salverda Merijn
André Van Der Ley Peter
Original Assignee
De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport filed Critical De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport
Publication of MX2017015404A publication Critical patent/MX2017015404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a composiciones de vacunas basadas en vesículas de membrana externa Gram-negativas que presentan antígenos de patógenos expresados como parte de una proteína de fusión que comprende partes N-terminales de lipoproteínas expresadas en la superficie de bacterias Gram-negativas, y uso de tales composiciones en vacunación. La invención se refiere además a las lipoproteínas de fusión que comprenden partes N-terminales de lipoproteínas expresadas en la superficie de bacterias Gram-negativas y antígenos de patógenos fusionados a las mismas, construcciones de ADN y células huésped bacterianas para expresar estas lipoproteínas de fusión y a métodos para producir vesículas de membrana externa que presentan las lipoproteínas de fusión.
MX2017015404A 2015-06-02 2016-06-02 Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas. MX2017015404A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170307 2015-06-02
PCT/EP2016/062494 WO2016193370A1 (en) 2015-06-02 2016-06-02 Surface display of antigens on gram-negative outer membrane vesicles

Publications (1)

Publication Number Publication Date
MX2017015404A true MX2017015404A (es) 2018-05-22

Family

ID=53365837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015404A MX2017015404A (es) 2015-06-02 2016-06-02 Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.

Country Status (11)

Country Link
US (2) US10639280B2 (es)
EP (1) EP3302511A1 (es)
JP (1) JP7008900B2 (es)
KR (1) KR102690377B1 (es)
CN (2) CN117247460A (es)
AU (1) AU2016269722B2 (es)
BR (1) BR112017025954A2 (es)
CA (1) CA2987306A1 (es)
HK (1) HK1253310A1 (es)
MX (1) MX2017015404A (es)
WO (1) WO2016193370A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018379236B2 (en) 2017-12-04 2025-02-27 Intravacc B.V. An improved process for producing outer membrane vesicles
CA3096849A1 (en) 2018-04-10 2019-10-17 The Administrators Of The Tulane Educational Fund Burkholderia pseudomallei complex outer membrane vesicles as adjuvants
US20210393768A1 (en) * 2018-08-27 2021-12-23 University Of Virginia Patent Foundation Compositions and methods for preventing and treating virus infection
CN111358942A (zh) * 2018-12-25 2020-07-03 国家纳米科学中心 一种疫苗及其制备方法
JP7462864B2 (ja) * 2019-04-19 2024-04-08 国立感染症研究所長 メンブレンヴェシクル
KR20220152402A (ko) * 2019-11-25 2022-11-15 그리피스 유니버시티 임균 감염에 대한 면역원성 단백질
CN111018998B (zh) * 2019-12-04 2021-10-29 杭州傲锐生物医药科技有限公司 一种莱姆重组融合蛋白OspC-VlsE及其应用
JP2023525294A (ja) * 2020-05-08 2023-06-15 イントラヴァック ベスローテン フェノーツハップ クリックｏｍｖ
WO2022011014A1 (en) * 2020-07-09 2022-01-13 Exocure Biosciences, Inc. Bacteria-derived vesicles and use thereof for generating immune response to sars-cov-2
US12364744B2 (en) * 2020-11-25 2025-07-22 Lankenau Institute For Medical Research Methods and compositions for the diagnosis, prophylaxis and treatment of Lyme disease
WO2026047244A1 (en) 2024-09-02 2026-03-05 Intravacc B.V. Modified meningococcal omvs
CN119570700B (zh) * 2024-09-10 2025-11-14 北京航空航天大学 重组益生菌利用t0ss分泌系统口服递送蛋白酶的方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US20020028215A1 (en) * 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
UA103316C2 (uk) * 2008-03-14 2013-10-10 Санофі Пастер Біолоджікс Ко. Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
WO2012041899A1 (en) * 2010-09-28 2012-04-05 Xbrane Bioscience Ab Fusion protein for secretory protein expression
RS57267B1 (sr) 2011-07-07 2018-08-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Postupak za proizvodnju vezikula spoljašnje membrane gram-negativne bakterije bez upotrebe deterdženta
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles

Also Published As

Publication number Publication date
AU2016269722A1 (en) 2017-12-07
US11040010B2 (en) 2021-06-22
KR102690377B1 (ko) 2024-08-01
CN107847532A (zh) 2018-03-27
CN117247460A (zh) 2023-12-19
BR112017025954A2 (pt) 2018-08-14
HK1253310A1 (zh) 2019-06-14
KR20180014756A (ko) 2018-02-09
AU2016269722B2 (en) 2021-06-24
EP3302511A1 (en) 2018-04-11
US20200197308A1 (en) 2020-06-25
JP7008900B2 (ja) 2022-02-10
JP2018521632A (ja) 2018-08-09
US10639280B2 (en) 2020-05-05
WO2016193370A1 (en) 2016-12-08
CA2987306A1 (en) 2016-12-08
US20180153808A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
MX2017015404A (es) Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
GB201607510D0 (en) Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (OMV) for delivery to the GI-tract
WO2015200357A3 (en) Nucleic acids for treatment of peanut allergies
MX363529B (es) Vesículas de membrana externa.
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
WO2016107818A8 (en) Compositions and methods for protein glycosylation
WO2018093932A3 (en) Nucleic acids for treatment of allergies
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
EP3225690A4 (en) Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use thereof
MX2022003706A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
EA201890914A1 (ru) Доставка белка бактериями
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2015000287A (es) Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente.
MX2016000075A (es) Particulas de rotavirus con proteinas de superficie quimericas.
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
PH12015502353A1 (en) Fusion polypeptides and vaccines
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
NZ725212A (en) Group a streptococcus vaccine
MX2016001678A (es) Construcciones de expresion y metodos para expresar polipeptidos en celulas eucariotas.
IN2013CN01528A (es)